Skip to content
Menu

Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $65

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $65.

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $65.

Read at benzinga.com